Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $66.6 million, a nearly 20% increase over 2024, with testing volume up over 11% and trailing 12-month ASP up over 7% [21][27][29] - Gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure experienced in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The company reset the volume run rate from approximately 30,000 tests in Q1 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [11][21] - The ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, driven by new product enhancements and improved revenue cycle management [12][21] Market Data and Key Metrics Changes - The company expanded its sales force from 40 to 45 territories in 2025, with expectations for improved productivity from new sales representatives over time [12][21] - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to be realized over the next 2-3 years [23] Company Strategy and Development Direction - The company aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovation to address significant unmet needs in the market [6][19] - The strategy includes advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product cadence [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable, profitable growth, guiding revenue expectations for 2026 to be between $70 million and $73 million [18][27] - The management highlighted the importance of achieving cash flow positivity and durable profitability, emphasizing the need for continued investment in commercial and R&D efforts [32][29] Other Important Information - The company is developing a solution for myositis, with plans to have it ready for commercialization by 2027, reflecting a strong demand from clinicians [36][16] - The American College of Rheumatology (ACR) has begun advocating for the company's AVISE platform, which is expected to enhance market access and support ASP growth [14][50] Q&A Session Summary Question: Why is it the right time to make investments despite profitability targets? - Management indicated that investments are necessary for durable cash flow positivity and to support long-term growth, with a focus on enhancing the commercial organization and R&D pipeline [32][35] Question: What is the commercialization target for myositis? - The company aims to have the myositis offering ready for the clinic by 2027, with ongoing internal feasibility studies and validation of assays [36] Question: What is the expected ASP for Q4 2026? - Management noted that while they have not disclosed the expected trailing twelve-month ASP, they anticipate stabilization and incremental gains in the second half of the year [38][39] Question: How is the Northwell Health situation impacting volume? - Management clarified that the Northwell situation was a one-time setback and that growth initiatives have compensated for any lost volume [39][40] Question: What is the status of the local coverage determination for rheumatologic diseases? - The company maintains regular contact with the team at MolDX regarding the draft LCD, which is expected to cover broader testing in rheumatologic conditions [71][72]

Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $66.6 million, a nearly 20% increase over 2024, with testing volume up over 11% and trailing 12-month ASP up over 7% [21][27][29] - Gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure experienced in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The company reset the volume run rate from approximately 30,000 tests in Q1 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [11][21] - ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, driven by new product enhancements and improved revenue cycle management [12][22] Market Data and Key Metrics Changes - The company expanded its sales force from 40 to 45 territories in 2025, with expectations for improved productivity from new sales representatives over time [12][21] - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to be realized over the next 2-3 years [23] Company Strategy and Development Direction - The company aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovation to address significant unmet needs in the market [6][18] - The strategy includes advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product cadence [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable, profitable growth, with revenue expectations for 2026 set between $70 million to $73 million [18][27] - The company is focused on creating a foundation for innovation and evaluating select inorganic opportunities to support long-term growth [19][20] Other Important Information - The company has five promising assets in development and plans to launch one product each year to expand its addressable market opportunity [15][16] - The American College of Rheumatology has begun advocating for the company's products, which is expected to drive medical policy progress with payers [14][50] Q&A Session Summary Question: Why is it the right time to make investments despite profitability targets? - Management indicated that investments in the commercial organization and R&D are necessary for durable cash flow positivity, emphasizing the importance of achieving sustainable growth [32][35] Question: What is the commercialization target for the myositis product? - The company aims to have the myositis offering ready for the clinic by 2027, with ongoing internal feasibility studies and validation of assays [36][37] Question: What is the expected ASP for Q4 2026? - Management did not disclose specific ASP figures but indicated that they expect stabilization and incremental gains in the second half of 2026 [39][40] Question: How is the Northwell Health situation affecting volume growth? - Management views the Northwell situation as a one-time setback and has seen growth initiatives compensate for any lost volume [40][41] Question: What is the status of the local coverage determination for rheumatologic disease? - The company maintains regular contact with the team at MolDX regarding the draft LCD, which is expected to cover broader testing in rheumatologic conditions [76][77] Question: What are medical directors asking about during discussions? - Medical directors are interested in understanding the clinical impact of the company's tests on patient outcomes and are looking for contemporary data to support their decisions [80][81]

Financial Data and Key Metrics Changes - In 2025, Exagen achieved record revenue of $66.6 million, a nearly 20% increase over 2024, driven by over 11% growth in testing volume and over 7% increase in trailing 12-month ASP [21][24] - The gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The volume run rate increased from approximately 30,000 tests in Q1 2025 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [12][21] - The ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, reflecting successful execution in revenue cycle management and product enhancements [13][21] Market Data and Key Metrics Changes - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to grow [23] - The company anticipates revenue for 2026 to be between $70 million and $73 million, with both volume and ASP growth contributing [19][27] Company Strategy and Development Direction - Exagen aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovative solutions to address significant unmet needs in autoimmune disease diagnosis [6][19] - The company is prioritizing three objectives: advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product development cadence [20][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity for ASP growth, driven by strategic initiatives that have improved ASP from $280 to $441 over the past three years [27][28] - The company is focused on achieving positive adjusted EBITDA and sustainable cash flow, with a breakeven revenue run rate now expected to be around $80 million [28][30] Other Important Information - Exagen has launched three sets of innovative markers into the clinic within an 18-month period, with ongoing efforts to streamline R&D and focus on high-potential projects [10][18] - The company is actively engaging with medical directors and has secured advocacy from the American College of Rheumatology, which is expected to enhance market access and support ASP growth [14][51] Q&A Session Summary Question: What is the rationale behind the recent investments and the adjusted profitability target? - Management indicated that the investments are aimed at ensuring durable cash flow positivity and enhancing the commercial organization, which is critical for long-term growth [32][34] Question: What is the status of the myositis product development? - The company is on track to have the myositis offering ready for commercialization by 2027, following internal feasibility studies and validation of assays [36] Question: How is the ASP expected to trend in 2026? - Management expects low single-digit ASP growth relative to Q4 2025 levels, with a focus on stabilizing and gradually increasing ASP throughout the year [37][60] Question: Can you provide an update on the Northwell Health situation and its impact on volume? - Management clarified that the Northwell situation was a one-time setback, and growth initiatives have compensated for any lost volume, with positive trends observed in Q4 [39][46] Question: What is the current status of the local coverage determination for rheumatologic diseases? - The local coverage determination is still in progress, and its outcome could significantly impact the company's future product offerings and market positioning [74][75]

Core Insights - Exagen Inc. reported a record revenue of $17.2 million for Q3 2025, marking a 38% increase compared to Q3 2024, or a 26% increase when excluding one-time adjustments from 2024 [8] - The company anticipates full-year revenue for 2025 to be between $65 million and $70 million, with expectations of achieving positive adjusted EBITDA in Q4 2025 [4] Financial Performance - Revenue for Q3 2025 was $17,244 thousand, compared to $12,507 thousand in Q3 2024, and for the nine months ended September 30, 2025, revenue was $49,944 thousand, up from $41,986 thousand in the same period of 2024 [2][18] - Gross margin improved to 58.4% in Q3 2025 from 55.8% in Q3 2024, and for the nine months, it was 59.3% compared to 58.7% [2] - Operating expenses increased to $13,175 thousand in Q3 2025 from $11,644 thousand in Q3 2024, and for the nine months, they rose to $38,688 thousand from $34,888 thousand [2][18] - The net loss for Q3 2025 was $7,087 thousand, compared to a net loss of $5,028 thousand in Q3 2024, with a nine-month net loss of $15,278 thousand versus $11,354 thousand in the prior year [2][18] Operational Highlights - The volume of AVISE CTD tests grew by 16% compared to Q3 2024, and the average selling price (ASP) for AVISE CTD tests increased to $441, up by $37 from Q3 2024 [8] - The company ended Q3 2025 with cash and cash equivalents of $35,652 thousand, an increase from $22,035 thousand at the end of Q3 2024 [2][18] - Exagen launched seronegative RA markers for anti-PAD4, enhancing the AVISE CTD panel, and presented six abstracts at the American College of Rheumatology Conference [8] Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focusing on improving clinical outcomes for patients with chronic autoimmune conditions through innovative testing solutions [13] - The company's flagship product, AVISE CTD, aids in the diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [13]

Core Insights - Exagen Inc. announced the acceptance of six abstracts at the 2025 American College of Rheumatology's annual meeting, highlighting advancements in autoimmune testing [1][2][3] Group 1: Research and Presentations - A plenary presentation in collaboration with Johns Hopkins University will focus on a urinary biomarker panel for guiding precision management of Lupus Nephritis [2][3] - Additional abstracts will cover innovative research on anti-RA33, anti-PAD4, and traditional biomarkers to improve rheumatoid arthritis diagnostic accuracy, as well as T Cell biomarkers to differentiate systemic lupus erythematosus from other conditions [2][3] - Exagen will present preliminary data on a novel kidney damage biomarker panel aimed at transforming early kidney disease management [3] Group 2: Abstract Details - The accepted abstracts include a plenary talk on "Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis" scheduled for October 27, 2025 [4] - Other presentations will feature a machine learning classifier for rheumatoid arthritis and a kidney-specific biomarker panel that differentiates Lupus Nephritis from diabetic kidney disease [4][5] - A poster presentation will discuss the clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products [6] Group 3: Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on improving patient care for chronic autoimmune conditions [7] - The company's flagship product, AVISE CTD, enhances the diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [7] - Exagen operates a CLIA-certified, CAP-accredited laboratory specializing in rheumatic disease testing, emphasizing research, innovation, and patient-centered care [7]

Financial Data and Key Metrics Changes - Exagen reported record revenue of $17.2 million for Q2 2025, representing a 14% year-over-year growth, marking the highest quarterly revenue in the company's history [5][23] - The average revenue per territory reached over $430,000 for the quarter, up from $285,000 two years ago, indicating significant commercial leverage [6] - Gross margin improved to just over 60%, up from about 59% in Q1 and 60% in Q2 2024, reflecting higher average selling prices (ASP) and normalization of lab operations [24] Business Line Data and Key Metrics Changes - The Advise CTD test volume growth was substantial, with the best quarterly volume since strategic adjustments were made in 2023 [6] - ASP for the trailing twelve months grew by $27 year-over-year to $428, driven primarily by new biomarkers [23] Market Data and Key Metrics Changes - The company is currently around 10% penetrated in its market, indicating significant room for growth [35] - The expansion of the physician base and consistent ordering patterns from high-value clinicians contributed to revenue growth [7][9] Company Strategy and Development Direction - Exagen is focused on building leadership in autoimmune diagnostics through disciplined execution, physician engagement, and innovation [5] - The company plans to launch additional biomarkers, including anti-PAD antibodies, to strengthen its value proposition in rheumatoid arthritis [54] - Strategic investments in R&D and commercial expansion are ongoing, with a focus on achieving profitability and improving patient outcomes [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of volume growth, attributing it to a strong team and the introduction of new biomarkers [35] - The company expects to achieve positive adjusted EBITDA by Q4 2025 and maintain it throughout 2026 [28] Other Important Information - Exagen ended the quarter with over $30 million in cash and equivalents, positioning itself for near free cash flow positive status [27] - The addition of key personnel, including a new Chief Scientific Officer, is expected to enhance the company's R&D capabilities [14] Q&A Session Summary Question: Sustainability of Volume Growth - Management believes the recent volume growth is sustainable due to a strong team and the introduction of new biomarkers, with a market penetration of just under 10% [35] Question: ASP Progress - Management remains optimistic about achieving a $90 increase in ASP by the end of 2025, despite some adjustments made to align accrual rates with cash collections [41] Question: Market Access Initiatives - The company is enhancing marketing campaigns and training for the sales team to drive awareness and adoption of its products, focusing on building trust within the clinical community [92] Question: Expansion of Territories - Exagen started Q2 with 40 territories and expanded to 42, with plans to reach 44 by year-end, emphasizing the importance of field-based representatives for growth [72][75]

Core Insights - Exagen Inc. has appointed Chas McKhann to its Board of Directors, effective July 17, 2025, enhancing its leadership team with his extensive experience in the life sciences industry [1][2]. Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on transforming care for patients with chronic autoimmune conditions. The company aims to improve clinical outcomes through its innovative testing portfolio, including its flagship product, AVISE® CTD, which aids in the diagnosis of complex autoimmune diseases [5]. Leadership Appointment - Chas McKhann brings over 25 years of experience in the life sciences sector, having held significant leadership roles in various medical technology companies. His previous positions include Board member, President, and CEO of Silk Road Medical and Apollo Endosurgery, both of which were acquired by Boston Scientific [2]. - The President and CEO of Exagen, John Aballi, expressed enthusiasm about McKhann's appointment, highlighting his leadership and commercial expertise as vital for driving growth and advancing patient care [3]. Strategic Vision - McKhann expressed his honor in joining Exagen's Board, emphasizing the company's commitment to innovation in autoimmune diagnostics and his eagerness to contribute to strategic growth and long-term value creation for all stakeholders [4].

Core Insights - Exagen Inc. has completed the sale of an additional 502,500 shares of common stock at a public offering price of $5.25 per share, resulting in gross proceeds of approximately $20.2 million [1][2] Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on transforming care for patients with chronic autoimmune conditions. The company aims to improve clinical outcomes through its innovative testing portfolio, including its flagship product AVISE® CTD, which aids in the diagnosis of complex autoimmune conditions [5] Offering Details - The public offering was conducted under a shelf registration statement on Form S-3, which was declared effective by the SEC on November 29, 2023. The offering included a final prospectus supplement that describes the terms of the offering [3] Underwriter Information - Canaccord Genuity acted as the sole bookrunner for the offering, facilitating the sale of all shares in the public offering [2]

Core Insights - Exagen Inc. reported a record revenue of $15.5 million for Q1 2025, reflecting a growth from $14.4 million in Q1 2024, driven by increased average selling price (ASP) and test volume growth [2][5] - The company anticipates full-year revenue of at least $65 million for 2025 and aims to achieve positive adjusted EBITDA by Q4 2025 [4][5] Financial Performance - Revenue for Q1 2025 was $15,498,000, up from $14,415,000 in Q1 2024, marking an increase of approximately 7.5% [2] - Gross margin decreased slightly to 58.9% in Q1 2025 from 59.6% in Q1 2024 [2] - Operating expenses rose to $12,488,000 in Q1 2025 from $11,601,000 in Q1 2024, leading to an operating loss of $3,365,000 compared to a loss of $3,003,000 in the previous year [2][5] - Net loss for Q1 2025 was $3,752,000, compared to a net loss of $3,360,000 in Q1 2024 [2][5] - Adjusted EBITDA for Q1 2025 was $(2,508,000), worsening from $(1,992,000) in Q1 2024 [2][20] Cash Position and Funding - As of March 31, 2025, the company had cash and cash equivalents of $11,194,000, down from $27,267,000 a year earlier [2][5] - The company closed a senior secured credit facility with Perceptive Advisors, securing $25 million to refinance existing debt and extend maturity [5] Product and Market Developments - The ASP for the AVISE CTD test increased to $419, a rise of $42 per test compared to Q1 2024 [5] - Exagen launched new biomarkers for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), with expected reimbursement around $90 per test [5] - The company is expanding its commercial reach with new sales territories identified [5] Research and Innovation - Exagen published a manuscript on T-cell research in a peer-reviewed journal, highlighting the clinical benefits of new SLE biomarkers [5] - Research on biomarkers for early kidney damage detection was presented at a significant industry summit [5]

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S. ...